Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling

Citations of this article
Mendeley users who have this article in their library.


Raf kinases are essential for normal Ras-Raf-MEK-ERK pathway signaling, and activating mutations in components of this pathway are associated with a variety of human cancers, as well as the related developmental disorders Noonan, LEOPARD, and cardiofaciocutaneous syndromes. Although the Raf kinases are known to dimerize during normal and disease-associated Raf signaling, the functional significance of Raf dimerization has not been fully elucidated. Here, using mutational analysis and a peptide inhibitor, we show that dimerization is required for normal Ras-dependent Raf activation and for the biological function of disease-associated Raf mutants with moderate, low, or impaired kinase activity. However, dimerization is not needed for the function of B-Raf mutants with high catalytic activity, such as V600E-B-Raf. Importantly, we find that a dimer interface peptide can effectively block Raf dimerization and inhibit Raf signaling when dimerization is required for Raf function, thus identifying the Raf dimer interface as a therapeutic target. © 2013 Elsevier Inc.




Freeman, A. K., Ritt, D. A., & Morrison, D. K. (2013). Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling. Molecular Cell, 49(4), 751–758. https://doi.org/10.1016/j.molcel.2012.12.018

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free